In the future, the safety and efficacy of different targeted immunotherapy combination strategies for BRAF V600E-mutant colorectal cancer can be further explored, such as combining BRAF V600E inhibitors with MEK inhibitors and PD-1 monoclonal antibodies. Here, MAP2K7 is linked to colorectal cancer.